Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22468947 | 0.98 | HPGDS (0.47) | HPGDSPARP1HTR2CHRH3TLR9 | |
| SCHEMBL14488002 | 0.88 | — | — | |
| SCHEMBL19862537 | 0.84 | NPC1 (0.40) | HPGDS | |
| SCHEMBL6633135 | 0.82 | NPC1 (0.42) | HPGDS | |
| SCHEMBL22860618 | 0.78 | PARP1 (0.44) | HPGDSPARP1HRH3TLR9TLR8 | |
| SCHEMBL17001709 | 0.77 | HPGDS (0.48) | HPGDSPARP1HRH3TLR9TLR8 | |
| Bromide SCHEMBL16992466 | 0.76 | HPGDS (0.47) | HPGDSPARP1HRH3TLR9TLR8 | |
| SCHEMBL28643814 | 0.73 | TLR8 (0.37) | HPGDSPARP1TLR8TLR7 | |
| SCHEMBL18845575 | 0.70 | HPGDS (0.81) | HPGDSHTR2CTLR9TLR8TLR7 | |
| SCHEMBL47075 | 0.70 | CHRM2 (0.41) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112250837-B | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin by thermal curing of solvent-free anhydride | 南京先进生物材料与过程装备研究院有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-112250837-A | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin through solvent-free anhydride thermosetting | 南京先进生物材料与过程装备研究院有限公司 | 2021-01-22 | — | — | CN | claimed |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2025-06-05 | — | — | US | disclosed |
| US-12240827-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3947360-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-113631548-B | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-112250837-B | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin by thermal curing of solvent-free anhydride | 南京先进生物材料与过程装备研究院有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220162183-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2022-05-26 | — | — | US | disclosed |
| EP-3947360-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | Zoetis Services LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113631548-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-112250837-A | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin through solvent-free anhydride thermosetting | 南京先进生物材料与过程装备研究院有限公司 | 2021-01-22 | — | — | CN | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020198478-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-1999006377-A1 | DERIVATIVES OF 1-((3,3-DIMETHYL-3-SILABUTOXY)METHYL)-2-(PHENYLSULFONYL)IMIDAZOLE | GLIATECH, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240827-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR5A | HPGDS 1202/4885PARP1 4048/4885HTR2C 10/4885 |
| US-20220162183-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | HPGDS 1202/4885PARP1 4048/4885HTR2C 10/4885 |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | HPGDS 1202/4885PARP1 4048/4885HTR2C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.